Financial Contrast: MediciNova (NASDAQ:MNOV) vs. Harrow (NASDAQ:HROW)

Harrow (NASDAQ:HROW) and MediciNova (NASDAQ:MNOV) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Profitability

This table compares Harrow and MediciNova’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Harrow	-13.51%	-38.00%	-3.37%
MediciNova	-1,168.70%	-26.51%	-24.39%

Risk and Volatility

Harrow has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500. Comparatively, MediciNova has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500.

Insider and Institutional Ownership

72.8% of Harrow shares are owned by institutional investors. Comparatively, 9.9% of MediciNova shares are owned by institutional investors. 12.8% of Harrow shares are owned by insiders. Comparatively, 14.0% of MediciNova shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Harrow and MediciNova”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$272.30 million	4.55	-$5.14 million	($1.00)	-33.08
MediciNova	$410,000.00	398.56	-$12.00 million	($0.21)	-15.81

Harrow has higher revenue and earnings than MediciNova. Harrow is trading at a lower price-to-earnings ratio than MediciNova, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Harrow and MediciNova, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1	2	9	0	2.67
MediciNova	1	1	3	2	2.86

Harrow currently has a consensus price target of $66.38, suggesting a potential upside of 100.65%. MediciNova has a consensus price target of $7.75, suggesting a potential upside of 133.43%. Given MediciNova’s stronger consensus rating and higher possible upside, analysts plainly believe MediciNova is more favorable than Harrow.

Summary

MediciNova beats Harrow on 9 of the 15 factors compared between the two stocks.

About Harrow

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

About MediciNova

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.